GranuFlo Lawsuit News: Bacterial Infection Risks Prompts NaturaLyte Recall, Bernstein Liebhard LLP Reports

The Firm is representing numerous individuals in GranuFlo lawsuits filed in the wake of the 2012 GranuFlo and NaturaLyte dialysis concentrate recall.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
Free Case Review
This development is of great interest to our Firm, as we are already representing numerous individuals who were allegedly injured by products included in the 2012 GranuFlo and NaturaLyte recall.

New York, NY (PRWEB) May 23, 2014

As GranuFlo lawsuits (http://www.injurybeacon.com/granuflo-dialysis/lawsuit/) filed in the wake of the 2012 GranuFlo and NaturaLyte dialysis drug recall continue to mount in courts throughout the U.S., Bernstein Liebhard LLP notes that the U.S. Food & Drug Administration (FDA) has announced another NaturaLyte recall for certain lots of the product that may pose a risk of bacterial infection. According to an alert issued by the agency on May 22, 2014, the affected lots of NaturaLyte Liquid Bicarbonate Concentrate, 6.4 liters, may develop higher than acceptable levels of bacteria during their shelf life. The potential contaminant has been identified as Halomonas, which can cause bacteremia or systemic infection.*

“This development is of great interest to our Firm, as we are already representing numerous individuals who were allegedly injured by products included in the 2012 GranuFlo and NaturaLyte recall,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering free GranuFlo lawsuit reviews to dialysis patients who allegedly suffered serious heart injuries related to the GranuFlo and NaturaLyte recall announced in 2012.

GranuFlo Lawsuits
GranuFlo and NaturaLyte are marketed by Fresenius Medical Care, and are used during hemodialysis treatments to remove toxins from the blood of kidney failure patients. The 2012 GranuFlo and NaturaLyte recall was announced after the products were tied to hundreds of cases of cardiac arrest in patients who underwent dialysis at Fresenius clinics in 2010. According to the recall notice, the two drugs converted to bicarbonate at higher levels than rival products. As such, inappropriate dosage could lead to a condition called metabolic alkalosis, as well as related cardiovascular injuries, including heart attacks, strokes and sudden cardiac death. The FDA granted Class I status to the 2012 GranuFlo and NaturaLyte recall because of the risk that the products could cause serious injuries or death.

Court documents indicate that more than 1,700 GranuFlo lawsuits have been filed in U.S. court since the recall was announced in 2012. The majority of these claims are pending in a federal multidistrict litigation underway in U.S. District Court, District of Massachusetts. Among other things, plaintiffs allege that Fresenius failed to provide adequate warnings regarding the risks associated with GranuFlo and NaturaLyte, and that the company continued to aggressively market the products even once it became aware of those risks. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

Dialysis patients who suffered heart attacks, strokes or other life-threatening cardiac events within 72 hours of a dialysis treatment that involved the administration of GranuFlo and NaturaLyte may be entitled to compensation. To learn more about filing a GranuFlo lawsuit, please visit Bernstein Liebhard LLP’s website, or the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For additional information, and to arrange for a free case review, please call 800-511-5092.

*fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm398553.htm, FDA, May 22, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.injurybeacon.com
https://plus.google.com/115936073311125306742?rel=author